Tice Connor, Seigerman Matthew, Fiorilli Paul, Pugliese Steven C, Khandhar Sameer, Giri Jay, Kobayashi Taisei
Department of Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA 19104 USA.
Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA 19104 USA.
Curr Cardiovasc Risk Rep. 2020;14(12):24. doi: 10.1007/s12170-020-00659-z. Epub 2020 Oct 6.
Over 100,000 cardiovascular-related deaths annually are caused by acute pulmonary embolism (PE). While anticoagulation has historically been the foundation for treatment of PE, this review highlights the recent rapid expansion in the interventional strategies for this condition.
At the time of diagnosis, appropriate risk stratification helps to accurately identify patients who may be candidates for advanced therapeutic interventions. While systemic thrombolytics (ST) is the mostly commonly utilized intervention for high-risk PE, the risk profile of ST for intermediate-risk PE limits its use. Assessment of an individualized patient risk profile, often via a multidisciplinary pulmonary response team (PERT) model, there are various interventional strategies to consider for PE management. Novel therapeutic options include catheter-directed thrombolysis, catheter-based embolectomy, or mechanical circulatory support for certain high-risk PE patients. Current data has established safety and efficacy for catheter-based treatment of PE based on surrogate outcome measures. However, there is limited long-term data or prospective comparisons between treatment modalities and ST. While PE diagnosis has improved with modern cross-sectional imaging, there is interest in improved diagnostic models for PE that incorporate artificial intelligence and machine learning techniques.
In patients with acute pulmonary embolism, after appropriate risk stratification, some intermediate and high-risk patients should be considered for interventional-based treatment for PE.
每年超过10万例心血管相关死亡由急性肺栓塞(PE)所致。虽然抗凝治疗一直是PE治疗的基础,但本综述强调了该病症介入治疗策略最近的迅速扩展。
在诊断时,适当的风险分层有助于准确识别可能适合进行高级治疗干预的患者。虽然全身溶栓(ST)是高危PE最常用的干预措施,但ST用于中危PE的风险状况限制了其应用。通过多学科肺反应团队(PERT)模型等方式评估个体患者风险状况后,对于PE管理有多种介入策略可供考虑。新的治疗选择包括导管定向溶栓、基于导管的栓子切除术,或为某些高危PE患者提供机械循环支持。目前的数据已基于替代结局指标确立了基于导管治疗PE的安全性和有效性。然而,长期数据有限,且治疗方式与ST之间的前瞻性比较也较少。虽然现代横断面成像改善了PE诊断,但人们对结合人工智能和机器学习技术的PE诊断模型改进也很感兴趣。
在急性肺栓塞患者中,经过适当的风险分层后,一些中高危患者应考虑接受基于介入的PE治疗。